<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03778723</url>
  </required_header>
  <id_info>
    <org_study_id>MD ∕17.08.07</org_study_id>
    <nct_id>NCT03778723</nct_id>
  </id_info>
  <brief_title>Effect of Propofol Midazolam on Cerebral Oxygenation and Metabolism During Clipping of Ruptured Cerebral Aneurysm</brief_title>
  <official_title>Cerebral Oxygenation and Metabolism in Patients Undergoing Clipping of Cerebral Aneurysm: A Comparative Study Between Propofol-based Total Intravenous Anesthesia and Sevoflurane-based Inhalational Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the theoretical benefits of i.v. agents, volatile agents remain popular. In a study
      comparing desflurane, isoflurane, and sevoflurane in a porcine model of intracranial
      hypertension, at equipotent doses and normocapnia, cerebral blood flow (CBF) and ICP were
      least with sevoflurane.

      Propofol is the most commonly used intravenous anesthetic. It has many theoretical advantages
      by reducing cerebral blood volume (CBV) and ICP and preserving both autoregulation and
      vascular reactivity. Neurosurgical patients anaesthetized with propofol were found to have
      lower ICP and higher CPP than those anaesthetized with isoflurane or sevoflurane.

      The well known pharmacodynamic advantages of intravenous anesthetics may give this group of
      drugs superior cerebral effects when compared with inhalation anesthetics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate the cerebral hemodynamics and global cerebral
      oxygenation as well as the systemic hemodynamic changes using midazolam and propofol as total
      intravenous anesthetics (TIVA) in comparison with sevoflurane anesthesia in clipping of
      ruptured cerebral aneurysm.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arterio-Jugular oxygen content difference</measure>
    <time_frame>Immediately before and every 30 min for 6 hour following start of surgery</time_frame>
    <description>The differences between arterial and jugular bulb oxygen contents</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated cerebral metabolic rate for O2 (eCMRO2)</measure>
    <time_frame>Immediately before and every 30 min for 6 hour following start of surgery</time_frame>
    <description>eCMRO2=Ca- jO2 x(PaCO2 ∕ 100), Where Ca jO2 is arterio-jugular O2 content difference. PaCO2 is arterial CO2 tension</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebral Extraction Rate of O2 (CEO2)</measure>
    <time_frame>Immediately before and every 30 min for 6 hour following start of surgery</time_frame>
    <description>Calculated as the differences between arterial and jugular bulb O2 saturations, CEO2 = SaO2 - SjvO2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebral Blood Flow equivalent (CBFe)</measure>
    <time_frame>Immediately before and every 30 min for 6 hour following start of surgery</time_frame>
    <description>: Which is an index of flow metabolism relationship, calculated as a reciprocal of arterio-jugular O2 content difference. CBFe = 1 ∕CaO2-CjvO.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Immediately before and every 30 min for 6 hour following start of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial blood pressure</measure>
    <time_frame>Immediately before and every 30 min for 6 hour following start of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral oxygen saturation</measure>
    <time_frame>Immediately before and every 30 min for 6 hour following start of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central venous pressure</measure>
    <time_frame>Immediately before and every 30 min for 6 hour following start of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End tidal carbon dioxide tension</measure>
    <time_frame>Immediately before and every 30 min for 6 hour following start of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation score</measure>
    <time_frame>For 6 hours from induction of anesthesia</time_frame>
    <description>- Postoperative level of sedation of all patients will be evaluated using Ramsay sedation scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for first analgesic request from extubation</measure>
    <time_frame>For 6 hours from induction of anesthesia</time_frame>
    <description>Time for first analgesic request from extubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stay in intensive care unit</measure>
    <time_frame>For 5 days after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ruptured Cerebral Aneurysm</condition>
  <arm_group>
    <arm_group_label>Total intravenous anesthesia (TIVA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive total intravenous anesthesia using Propofol and Midazolam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhalation Anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive Inhalation anesthesia using Sevoflurane</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Total intravenous anesthesia (TIVA)</intervention_name>
    <description>Propofol (1.5-2 mg/kg/h) infusion, Midazolam (0.12 mg/kg/h) infusion</description>
    <arm_group_label>Total intravenous anesthesia (TIVA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhalation Anesthesia</intervention_name>
    <description>Sevoflurane at a concentration of 2-2.5%</description>
    <arm_group_label>Inhalation Anesthesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rescue fentanyl</intervention_name>
    <description>Fentanyl in repeated doses (50 µg) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value) are used for maintenance of analgesia</description>
    <arm_group_label>Inhalation Anesthesia</arm_group_label>
    <arm_group_label>Total intravenous anesthesia (TIVA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologists physical status III or IV.

        Exclusion Criteria:

          -  Morbid obese patients.

          -  Severe or uncompensated cardiovascular diseases

          -  Severe or decompensated renal diseases

          -  Severe or decompensated hepatic diseases

          -  Severe or decompensated endocrinal diseases.

          -  Pregnancy

          -  Postpartum

          -  Lactating females

          -  Allergy to one of the agents used.

          -  Severely altered consciousness level.

          -  Sitting or prone position during surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherif A Mousa, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammed A Ghanem, MD</last_name>
    <role>Study Director</role>
    <affiliation>Associate Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherif A Mousa, MD</last_name>
    <phone>00201001637298</phone>
    <phone_ext>00201067883998</phone_ext>
    <email>s_abdomousa@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohammed A Ghanem, MD</last_name>
    <phone>00201067883998</phone>
    <phone_ext>00201067883998</phone_ext>
    <email>Mohamed.abdel_latif@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sherif A Mousa</name>
      <address>
        <city>Mansourah</city>
        <state>DK</state>
        <zip>050</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Mohammed A Ghanem, MD</last_name>
      <phone>00201067883998</phone>
      <email>Mohamed.abdel_latif@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Sherif A Mousa, MD</last_name>
      <phone>00201001637298</phone>
      <phone_ext>00201001637298</phone_ext>
      <email>s_abdomousa@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kareem EM El-Emam, MSec</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maha Y Youssef, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>December 16, 2018</study_first_submitted>
  <study_first_submitted_qc>December 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>December 16, 2018</last_update_submitted>
  <last_update_submitted_qc>December 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

